Wednesday, 30 March 2016

Transmission of CJD and Variant CJD by Blood and Blood Products


A new FDA guidance document has been issued: “Revised Preventive Measures to Reduce the Possible Risk of Transmission of CJD and Variant CJD by Blood and Blood Products.”

Tests are being developed to detect CJD and vCJD infections in blood and plasma donors. However, until suitable donor screening tests become available, FDA continues to recommend interim preventive measures based on the available scientific data and the evolving state of knowledge regarding these diseases. FDA may update this guidance in the future, in light of developments in testing technology, epidemiological information, and the impact of these recommendations on the supply of blood and blood-derived products.

For details see: FDA

Posted by Dr. Tim Sandle